This compound has a stronger human clinical evidence base than typical research peptides, but it still requires clinician oversight and approved-use context.
Overview
Tirzepatide (Mounjaro, Zepbound) is a dual agonist that activates both the GIP and GLP-1 receptors. It is FDA-approved and prescription-available, and has shown notable results in weight-management trials.
How It's Thought to Work
By activating both GIP and GLP-1 receptors, tirzepatide influences insulin secretion, appetite, and gastric emptying, with effects that trials suggest may exceed GLP-1 agonism alone.
What the Research Says
Backed by the SURPASS (diabetes) and SURMOUNT (obesity) human clinical trial programs — large, randomized, and peer-reviewed.
Key studies to start with
Case Report: GADA-positive type 1 diabetes with diabetic ketoacidosis in a young adult with obesity temporally associated with unsupervised tirzepatide use for weight reduction
Frontiers in endocrinology · 2026
PubMedGLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubes
GeroScience · 2026 Nov 4
PubMedClinical outcomes of tirzepatide in a real-world follow-up cohort of patients with type 2 diabetes
TouchREVIEWS in endocrinology · 2026 Oct
Regulatory & Legal Status
FDA-approved and prescription-only. Compounded and gray-market versions raise safety and quality concerns.
Safety Considerations
GI side effects are common; contraindications and warnings apply. Use only under a prescribing clinician.